The success of efforts to introduce new pre-exposure prophylaxis (PrEP) methods for HIV prevention, such as the PrEP ring and injectable CAB PrEP, will also rely on local partners. That’s why one of MOSAIC’s five strategic objectives is dedicated to strengthening local partner capacity to design and implement high-quality product introduction activities and research.
Continue Reading
The HIV Prevention Ambassador Training Package is designed to support the meaningful engagement of youth “Ambassadors” in helping adolescent girls and young women (AGYW) remain free from HIV. Recognizing young people as full partners in HIV prevention is a key step toward equalizing the response to the epidemic — today’s World AIDS Day theme and call to action.
Continue Reading
We know that adolescent girls and young women live complex lives full of important relationships that shape the decisions they make. Yet too often efforts to generate demand for PrEP fail to reach beyond the individual user to her support system—those trusted people in her life who she leans on when making important choices. But demand generation for PrEP is evolving.
Continue Reading
PrEP-it — launched in 2019 as a Microsoft Excel-based tool for pre-exposure prophylaxis (PrEP) programs and then as a more user-friendly online tool in 2021 — had been used in only a handful of countries prior to August 2022 to set targets for PrEP coverage and forecast commodity needs. Given the response to two recent workshops held in Lusaka, Zambia, that is changing now.
Continue Reading
For the MOSAIC project team, the AIDS 2022 conference set the stage for embracing the introduction of new biomedical HIV prevention products and generating evidence on how to support choice and effective use. We attended the conference virtually and took away three key messages that resonate with our work on MOSAIC.
Continue Reading
Since oral PrEP was first approved for use in 2012, dozens of countries have approved the product and use is expanding. But the pace of scale-up has been slower than expected and PrEP remains out of reach for many who may benefit from it.
Continue Reading
In this photo story, MOSAIC NextGen Squad representatives introduce themselves through their stories. They share their passions, what led them to work in HIV prevention, their thoughts on MOSAIC, and their hopes and dreams for the future.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
Sub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa.
Continue Reading
With the dapivirine vaginal ring and injectable cabotegravir poised to join oral pre-exposure prophylaxis (PrEP) as safe, effective HIV prevention products, people seeking an HIV prevention method that works for them will soon have real choices.
Continue Reading